tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Morris R Modes of action of FK506, cyclosporin A, and rapamycin. 1994 Transplant. Proc. pmid:7527964
Ericzon BG Early graft function in liver transplantation patients. 1994 Transplant. Proc. pmid:7527965
Ricordi C et al. Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. 1994 Transplant. Proc. pmid:7527967
Lhöest GJ et al. 15-Desmethyl FK-506 and 15,31-desmethyl FK-506 from human liver microsomes: isolation, identification (by fast atom bombardment mass spectrometry and NMR), and evaluation of in vitro immunosuppressive activity. 1994 Clin. Chem. pmid:7513627
Tsugita M et al. Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. 1994 Transplant. Proc. pmid:7527969
Ueda H et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. 1994 J. Antibiot. pmid:7513682
Asselin I et al. Polymerase chain reaction-based assay to assess the success of myoblast transplantation in mdx mice. 1994 Transplant. Proc. pmid:7527970
Tai J et al. Effect of FK506 on rat Leydig cell function--in vivo and in vitro study. 1994 Metab. Clin. Exp. pmid:7513780
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Egawa H et al. FK506 conversion therapy in pediatric liver transplantation. 1994 Transplantation pmid:7513911
Reggiani P et al. Conversion to rescue therapy with FK 506: data from eight liver transplant patients. 1994 Transplant. Proc. pmid:7527982
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Arakawa H et al. Molecular cloning and expression of a novel human gene that is highly homologous to human FK506-binding protein 12kDa (hFKBP-12) and characterization of two alternatively spliced transcripts. 1994 Biochem. Biophys. Res. Commun. pmid:7513996
Langrehr JM et al. Mucosal recipient-type mononuclear repopulation and low-grade chronic rejection occur simultaneously in indefinitely surviving recipients of small bowel allografts. 1994 Transpl. Int. pmid:7513999
Leach KL et al. A soluble binding assay for measuring 3H-FK506 binding to the hsp56 immunophilin. 1994 J Immunoassay pmid:7530727
Genestier L et al. Cyclosporin A and FK506 inhibit activation-induced cell death in the murine WEHI-231 B cell line. 1994 Cell. Immunol. pmid:7514101
Atcherson MM and Trifillis AL Cytotoxic effects of FK506 on human renal proximal tubule cells in culture. 1994 In Vitro Cell. Dev. Biol. Anim. pmid:7529625
Maruyama K et al. FK 506 for vascular permeability factor production in minimal change nephrotic syndrome. 1994 Nephron pmid:7517020
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Peattie DA et al. Three distinct messenger RNAs can encode the human immunosuppressant-binding protein FKBP12. 1994 Gene pmid:7529739
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Shipston MJ et al. Glucocorticoid negative feedback in pituitary corticotropes. Pivotal role for calcineurin inhibition of adenylyl cyclase. 1994 Ann. N. Y. Acad. Sci. pmid:7529975
Firdaous I et al. Pediatric intravenous FK506--how much are we really infusing? 1994 Transplantation pmid:7517079
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Dawson VL et al. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. 1994 Neuropharmacology pmid:7532825
Igarashi T et al. Central nervous system toxicity related to FK506 in patients with Behçet's disease. 1994 Ann. Rheum. Dis. pmid:7517134
Ellis D et al. Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. 1994 Pediatr. Nephrol. pmid:7517171
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Okamoto M et al. Detection of allograft rejection in rat small bowel transplantation by analysing the in situ distribution of S-phase lymphocytes. 1994 Transplant. Proc. pmid:7518145
Ippoliti G et al. Serum cytokine levels after small bowel transplantation in pigs. 1994 Transplant. Proc. pmid:7518146
Orita T et al. Effect of FK 506 in combination with prednisolone on the graft-vs-host reaction after small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7518147
Alessiani M et al. Total orthotopic small bowel transplantation in swine under FK 506. 1994 Transplant. Proc. pmid:7518148
Jain A et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. 1994 Transplant. Proc. pmid:7518149
Takara T et al. Intraportal donor-specific transfusion given 24 hours before small bowel transplantation with cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7518150
Kusne S et al. Infectious complications after small bowel transplantation in adults. 1994 Transplant. Proc. pmid:7518153
Porayko MK et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. 1994 Mayo Clin. Proc. pmid:7508536
Martin MF Nephrotoxic effects of immunosuppression. 1994 Mayo Clin. Proc. pmid:7508537
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Erden E et al. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. 1994 Transplantation pmid:7519801
Dilling MB et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. 1994 Cancer Res. pmid:7508822
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. 1994 Lancet pmid:7520105
Funauchi M et al. Effects of an inhibitor for calcium/calmodulin-dependent protein phosphatase, calcineurin, on induction of long-term potentiation in rat visual cortex. 1994 Neurosci. Res. pmid:7520143
Ito T et al. Protective effects of gabexate mesilate on acute pancreatitis induced by tacrolimus (FK-506) in rats in which the pancreas was stimulated by caerulein. 1994 J. Gastroenterol. pmid:7520321
Zeniya A et al. Anti-ulcer effect of FK 506, immunosuppressive agent, in rats. 1994 J. Gastroenterol. pmid:7520322
Dawson TM et al. Nitric oxide: cellular regulation and neuronal injury. 1994 Prog. Brain Res. pmid:7533914
Connelly PR et al. Enthalpy of hydrogen bond formation in a protein-ligand binding reaction. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7510408
Shiraga T et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. 1994 Biochem. Pharmacol. pmid:7510480
Hossain M et al. Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. 1994 Arerugi pmid:7520689
Bell A et al. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin. 1994 Biochem. Pharmacol. pmid:7520696
Paslaru L et al. GRP78 induction by cyclosporin A in human HeLa cells. 1994 FEBS Lett. pmid:7520875
Gailliot FP et al. Isolation and characterization of the major equilibrium product of FK-520. 1994 J. Antibiot. pmid:7520900
Stancato LF et al. The native v-Raf.hsp90.p50 heterocomplex contains a novel immunophilin of the FK506 binding class. 1994 J. Biol. Chem. pmid:7520912
Hirano Y et al. Mechanism of FK506-induced glucose intolerance in rats. 1994 J Toxicol Sci pmid:7520947
Tacrolimus (FK506) for organ transplants. 1994 Med Lett Drugs Ther pmid:7520968
Bierer BE Biology of cyclosporin A and FK506. 1994 Prog. Clin. Biol. Res. pmid:7536944
Malyszko J et al. FK 506 affects platelet aggregation in vitro. 1994 Thromb. Res. pmid:7521072
Tai PK et al. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 1994 Biochemistry pmid:7521210
Akita K et al. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. 1994 Clin. Exp. Pharmacol. Physiol. pmid:7521274
Weaver JL et al. The interaction of immunosuppressive compounds in tandem stimulated peripheral human lymphocytes. 1994 Immunopharmacol Immunotoxicol pmid:7521360
Bram RJ and Crabtree GR Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. 1994 Nature pmid:7522304
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Todo S et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. 1994 Ann. Surg. pmid:7522431
Ueda K et al. Human P-glycoprotein as a multi-drug transporter analyzed by using transepithelial transport system. 1994 Jpn. J. Physiol. pmid:7538609
Lebeau MC et al. Rabbit FKBP-59/HBI does not inhibit calcineurin activity in vitro. 1994 Biochem. Biophys. Res. Commun. pmid:7522447
Mouzaki A and Rungger D Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated or drug-treated naive and memory T-helper cells. 1994 Blood pmid:7522636
Abu-Elmagd K et al. Three years clinical experience with intestinal transplantation. 1994 J. Am. Coll. Surg. pmid:7522850
Holländer GA et al. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. 1994 Transfus Sci pmid:10155542
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Takahara S et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. 1994 Transplant. Proc. pmid:7524219
Heitman J et al. Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 1994 Transplant. Proc. pmid:7524220
Yoshimura R et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7524223
Kupferman JC et al. Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. 1994 Transplant. Proc. pmid:7524224
Kattner A et al. Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA malabsorption. 1994 Transplant. Proc. pmid:7524225
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
Bush KT et al. Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. 1994 Biochem. J. pmid:7526846
Kahan BD New immunosuppressive drugs--pharmacologic approaches to alter immunoregulation. 1994 Ther Immunol pmid:7584478
Bismuth H et al. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. 1994 Transpl. Int. pmid:11271231
Akamine S et al. Monitoring canine lung allograft rejection using Ia antigen expression by bronchoalveolar lymphocytes. 1994 Surg. Today pmid:7526914
Tsuchida M et al. The effects of FK506 and dexamethasone on rat thymocyte differentiation. 1994 Ther Immunol pmid:7584489
McMaster P Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A. 1994 Transpl. Int. pmid:11271239
Lemoine A et al. FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation. 1994 Hepatology pmid:7527003
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. 1994 Transpl. Int. pmid:11271254
Alnemri ES et al. FKBP46, a novel Sf9 insect cell nuclear immunophilin that forms a protein-kinase complex. 1994 J. Biol. Chem. pmid:7527037
D'Silva M et al. The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation. 1994 Transpl. Int. pmid:11271257
Todo S et al. Small intestinal transplantation in humans with or without the colon. 1994 Transplantation pmid:7512291
Rosenwirth B et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. 1994 Antimicrob. Agents Chemother. pmid:7527198
Trocha K et al. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. 1994 Transpl. Int. pmid:11271273
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Shaw LM and Brayman KL FK-506 therapeutic drug monitoring. 1994 Clin. Chem. pmid:7527305
Ishii T et al. Immunodepressants ameliorate normothermic ischemia injury to the rat liver by down-regulating tumor necrosis factor, not by alleviation of lipid peroxidative injury. 1994 Transpl. Int. pmid:11271294
Jordan ML et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. 1994 Transplantation pmid:7512293
Winkler M et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression. 1994 Clin. Chem. pmid:7527306
Platz KP et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. 1994 Transpl. Int. pmid:11271297
Wijdicks EF et al. FK506-induced neurotoxicity in liver transplantation. 1994 Ann. Neurol. pmid:7512320
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: dynamic effects of ligand binding and implications for calcineurin recognition. 1994 Biochemistry pmid:7512379
Mori A et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. 1994 Int. Arch. Allergy Immunol. pmid:7512393
Okubo Y et al. Cytokine production in patients with mite-sensitive bronchial asthma. 1994 Int. Arch. Allergy Immunol. pmid:7512395